Expert Opinion on Biological Therapy, Год журнала: 2024, Номер 24(11), С. 1261 - 1269
Опубликована: Окт. 21, 2024
Introduction Alzheimer's disease can cause dementia through brain matter degradation. This study investigates the monoclonal antibody usage for AD treatment, following PRISMA 2020 guidelines, and aims to discern that offers optimal balance of efficacy safety individuals with AD.
Язык: Английский
Cell, Год журнала: 2023, Номер 186(20), С. 4260 - 4270
Опубликована: Сен. 1, 2023
Язык: Английский
Процитировано
149
Brain, Год журнала: 2023, Номер 146(10), С. 3969 - 3990
Опубликована: Май 15, 2023
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's disease have created excitement and been heralded as corroboration the amyloid cascade hypothesis. However, while Aβ may contribute to disease, genetic, clinical, imaging biochemical data suggest a more complex aetiology. Here we review history weaknesses hypothesis in view new evidence obtained anti-amyloid antibodies. These indicate treatments either no or uncertain effect on cognition. Despite importance definition argue point playing minor aetiological role. We also discuss suggesting concerted activity many pathogenic factors propose evolving multi-factor models will better underpin search effective strategies treat disease.
Язык: Английский
Процитировано
125
Ageing Research Reviews, Год журнала: 2023, Номер 90, С. 102012 - 102012
Опубликована: Июль 7, 2023
Язык: Английский
Процитировано
47
Protein & Cell, Год журнала: 2024, Номер unknown
Опубликована: Май 11, 2024
Abstract Alzheimer’s disease (AD), the leading cause of dementia, is characterized by accumulation amyloid plaques and neurofibrillary tangles in brain. This condition casts a significant shadow on global health due to its complex multifactorial nature. In addition genetic predispositions, development AD influenced myriad risk factors, including aging, systemic inflammation, chronic conditions, lifestyle, environmental exposures. Recent advancements understanding pathophysiology are paving way for enhanced diagnostic techniques, improved assessment, potentially effective prevention strategies. These discoveries crucial quest unravel complexities AD, offering beacon hope management treatment options millions affected this debilitating disease.
Язык: Английский
Процитировано
32
The Journal of Prevention of Alzheimer s Disease, Год журнала: 2025, Номер unknown, С. 100094 - 100094
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
3
Brain Communications, Год журнала: 2023, Номер 5(3)
Опубликована: Янв. 1, 2023
Abstract The clinical benefit associated with anti-amyloid immunotherapies, a new class of drugs for the treatment Alzheimer’s disease, is predicated on their ability to modify disease course by lowering brain amyloid levels. At time writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food Drug Administration accelerated approval, further agents this in pipeline. Based limited published trial data date, regulators, payors physicians will need assess efficacy, effectiveness safety, as well cost accessibility. We propose that attention three important questions related safety should guide evidence-based consideration drugs. These are: (1) Were statistical analyses appropriate did they convincingly support claims efficacy? (2) Do reported effects outweigh concerns are generalizable representative population people disease? (3) demonstrate modification, suggesting increasing benefits beyond duration trials likely? suggest specific approaches interpreting results these highlight areas uncertainty where additional cautious interpretation existing warranted. Safe, effective accessible treatments eagerly awaited millions patients caregivers worldwide. While amyloid-targeting immunotherapies may be promising disease-modifying treatments, rigorous unbiased assessment critical regulatory decision-making subsequently determining provision utility routine practice. Our recommendations provide framework appraisal payors, patients.
Язык: Английский
Процитировано
39
The Lancet Regional Health - Americas, Год журнала: 2023, Номер 20, С. 100467 - 100467
Опубликована: Март 1, 2023
In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical evidence demonstrating drug's cognitive benefits. The manufacturer initially priced drug at staggering $56,000 per year, price that was later reduced $28,200. Unfortunately, these costs do not include additional expenses associated with monitoring treatment. However, Centers Medicare Medicaid Services (CMS) recently announced they will only cover individuals enrolled in trials limit coverage future antibodies. This discrepancy between FDA CMS positions has caused confusion concerns patients who could potentially benefit from therapy. It is important acknowledge economic uncertainties surrounding aducanumab its potential impacts on development processes. FDA's approval, limited evidence, raises questions about integrity rigor process. high cost also accessibility concerns, especially those without insurance or sufficient financial resources. Given CMS's policy, it's critical evaluate long-term implications this decision development. Without adequate support providers, treatments may be hindered. summary, pricing coupled created confusing concerning landscape patients. It's stakeholders, including patients, clinicians, insurers, regulatory bodies, work together address challenges ensure have access effective, affordable treatments.
Язык: Английский
Процитировано
37
Alzheimer s & Dementia, Год журнала: 2023, Номер 20(2), С. 1284 - 1297
Опубликована: Ноя. 20, 2023
Blood biomarkers have proven useful in Alzheimer's disease (AD) research. However, little is known about their biological variation (BV), which improves the interpretation of individual-level data.
Язык: Английский
Процитировано
30
Journal of Managed Care & Specialty Pharmacy, Год журнала: 2023, Номер 29(9), С. 1078 - 1083
Опубликована: Авг. 23, 2023
Язык: Английский
Процитировано
25
Bioengineering, Год журнала: 2023, Номер 10(2), С. 253 - 253
Опубликована: Фев. 15, 2023
As the most common form of dementia and a progressive neurodegenerative disorder, Alzheimer’s disease (AD) affects over 10% world population with age 65 older. The is neuropathologically associated loss neurons synapses in specific brain regions, deposition amyloid plaques neurofibrillary tangles, neuroinflammation, blood–brain barrier (BBB) breakdown, mitochondrial dysfunction, oxidative stress. Despite intensive effort, there still no cure for disorder. Stem cell-derived exosomes hold great promise treating various diseases, including AD, as they contain variety anti-apoptotic, anti-inflammatory, antioxidant components. Moreover, stem also promote neurogenesis angiogenesis can repair damaged BBB. In this review, we will first outline major neuropathological features AD; subsequently, discussion cells, cell-secreted exosomes, exosome isolation methods follow. We then summarize recent data involving use mesenchymal cell- or neural AD. Finally, briefly discuss challenges, perspectives, clinical trials using AD therapy.
Язык: Английский
Процитировано
24